Skip to content

The iStep Study: Development and Validation of an Incremental Exercise Step Test for Children With Cystic Fibrosis

The iStep Study: Development and Validation of an Incremental Exercise Step Test for Children With Cystic Fibrosis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02199340
Enrollment
24
Registered
2014-07-24
Start date
2011-07-31
Completion date
2014-10-31
Last updated
2016-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis

Keywords

Exercise testing, Children, Exercise capacity

Brief summary

The progression of lung disease in cystic fibrosis (CF) results inevitably in a reduction in exercise capacity. The assessment of fitness and exercise capacity in CF is an important measure of the impact of the disease process, particularly if it is repeated over time. With recent advances in clinical management, CF lung disease in children can be relatively mild and exercise tolerance good. The currently available field tests e.g. 3 minute step test, are often completed too easily. These tests provide limited information relating to maximal exercise performance. By contrast, the maximal CardioPulmonary Exercise Test (CPET), a progressive, incremental, gold standard exercise test with breath by breath analysis of expired gas, has proved to be a valuable means of assessing exercise response in patients with CF. Its only limitation is the requirement for specialist laboratory facilities, equipment and staff. A new field test for evaluating exercise capacity in children is needed. This should be portable, easy to administer and simple to perform by young children, while providing a higher intensity of exercise which correlates with day to day activity patterns of children, and clinically relevant information in the short term and longitudinally. This test needs to be a good surrogate measure of exercise capacity when formal CPET is unable to be undertaken. By providing accurate and useful information the results can be used to prescribe and train individuals with CF safely and effectively and can also be used in the short and long term for guidance of the medical management of these complex patients. The aim of this study is to develop and validate the use of a new incremental step test to assess exercise tolerance/capacity in children with CF, compare this with the gold standard CPET and to provide normative healthy control comparison data The main objectives of the study are 1. To develop an incremental step test to assess exercise tolerance / capacity in children with CF. 2. To compare the incremental step test with the gold standard CPET 3. To assess the level of exercise response produced by the incremental step test 4. To assess the correlation between independent variables of lung function measurements, age, weight and height with VO2peak and other exercise test outcomes 5. To assess the repeatability and evaluate the normal variability of the new incremental step test 6. To provide healthy control normative data for comparison

Interventions

OTHERiStep exercise test

newly developed submaximal exercise test

OTHERCPET exercise test

maximal gold standard exercise test

Sponsors

Great Ormond Street Hospital for Children NHS Foundation Trust
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
6 Years to 16 Years
Healthy volunteers
No

Inclusion criteria

Clinical population inclusion * Parental/guardian consent * Participant assent * Male or female * Confirmed Cystic fibrosis diagnosis (by genetic genotype or positive sweat test) * Receiving physiotherapy as part of their usual care * Height \>125cm to allow cycle ergometer use * 6-16 years Healthy control population inclusion * Parental/guardian consent * Participant assent * Male or female * 6-16 years

Exclusion criteria

Clinical population exclusion * \<6 years and \>16 years * No consent / assent * Frank haemoptysis in the last 48 hours * Acute infective exacerbation (defined as increased temperature, additional antibiotics) * Poor dietary intake/hydration * Oxygen dependent at rest * Arterial oxygen saturation (SaO2) \<90% at rest * Burkholderia cepacia * Coexisting insulin dependent diabetes mellitus * Methicillin-resistant Staphylococcus aureus (MRSA) positive Healthy control population exclusion * \<6 years and \>16 years * No consent / assent * Acute infection (defined as increased temperature and antibiotics)

Design outcomes

Primary

MeasureTime frameDescription
Peak oxygen uptake (VO2peak)Measured during the exercise test, day 1, maximum of 20 minutesGold standard exercise test to determine peak oxygen uptake during exercise

Secondary

MeasureTime frameDescription
Secondary breath by breath analysis outcome measuresMeasured during the exercise test, day 1, maximum of 20 minutes
Newly developed iStep exercise test outcome variablesMeasured during the exercise test, day 1, maximum of 20 minutesStandard field exercise test outcomes of heart rate, oxygen saturations, time, level achieved, rate of perceived exertion, perceived breathlessness
Height, weight and body mass index measuresMeasured at baseline on the day of testing, day 1, maximum of 5 minutesHeight, weight and body mass index will be measured for descriptive purposes only
Reasons for termination of the incremental step testMeasured at the end of the exercise test, day 1, maximum of 5 minutes

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026